Get started
Author

Yuji Minegishi

Observed names: Minegishi, Yuji, Y Minegishi, Y. Minegishi, YUJI MINEGISHI
ORCID: 0000-0001-5023-8058
Observed ORCID: 0000-0001-5023-8058
OpenAlex ID: A5103051890
Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
2004 · Kiyotaka Yoh, Genichiro Ishii, et al. · Clinical Cancer Research · 245
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
2014 · Satoshi Watanabe, Yuji Minegishi, et al. · Journal of Thoracic Oncology · 207
PDF
Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation
2002 · Kazuyoshi Kato, Tsutomu Ogura, et al. · Oncogene · 200
MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
2013 · Kazuhiro Kitamura, Masahiro Seike, et al. · Molecular Cancer Therapeutics · 195
PDF
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
2012 · MENGRU CAO, MASAHIRO SEIKE, et al. · International Journal of Oncology · 174
PDF
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
2012 · Makoto Maemondo, Yuji Minegishi, et al. · Journal of Thoracic Oncology · 156
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
2019 · Hiroaki Akamatsu, Kiichiro Ninomiya, et al. · International Journal of Clinical Oncology · 153
PDF
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
2010 · Yuji Minegishi, Junko Sudoh, et al. · Lung Cancer · 150
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
2005 · Y Kokubo, A Gemma, et al. · British Journal of Cancer · 137
PDF
Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy
2009 · Yuji Minegishi, Kiyoshi Takenaka, et al. · Internal Medicine · 130
PDF
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
2022 · Kohei Otsubo, Junji Kishimoto, et al. · European Respiratory Journal · 95
The Feasibility Study of Carboplatin Plus Etoposide for Advanced Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias
2011 · Yuji Minegishi, Hidehiko Kuribayashi, et al. · Journal of Thoracic Oncology · 73
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
2006 · Rintaro Noro, Akihiko Gemma, et al. · BMC Cancer · 69
PDF
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
2019 · Takashi Ogura, Nagio Takigawa, et al. · Respiratory Investigation · 54
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
2013 · Akihiko Miyanaga, Kumi Shimizu, et al. · BMC Cancer · 53
PDF
PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
2007 · Shoji Kudoh, Akinobu Yoshimura, et al. · International Journal of Oncology · 52
PDF
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
2018 · Akiko Takahashi, Masahiro Seike, et al. · Scientific Reports · 51
PDF
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
2012 · Kazuhiro Kitamura, Kaoru Kubota, et al. · Cancer Chemotherapy and Pharmacology · 51
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
2020 · Teppei Sugano, Masahiro Seike, et al. · Thoracic Cancer · 50
PDF
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis
2017 · Kohei Otsubo, Junji Kishimoto, et al. · Clinical Lung Cancer · 47
miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma
2014 · KAZUO YAMAMOTO, MASAHIRO SEIKE, et al. · Oncology Reports · 47
PDF
Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
2006 · Akihiko Gemma, Cai Li, et al. · BMC Cancer · 47
PDF
Histone deacetylase inhibitor enhances sensitivity of non‐small‐cell lung cancer cells to 5‐FU/S‐1 via down‐regulation of thymidylate synthase expression and up‐regulation of p21 waf1/cip1 expression
2010 · Rintaro Noro, Akihiko Miyanaga, et al. · Cancer Science · 43
PDF
Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
2014 · Yuji Minegishi, Nariaki Kokuho, et al. · Lung Cancer · 40
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
2020 · Yuji Minegishi, Akihiko Gemma, et al. · ERJ Open Research · 34
PDF
Works count: 135
Citation count: 3,176
H-index: 30
I10-index: 49
Year
Topic
Type